论文部分内容阅读
3月19日,格华止(二甲双胍)的原研企业默克集团旗下生物制药业务分支默克雪兰诺公司,与格华止当前在华的生产与销售企业中美上海施贵宝制药有限公司(百时美施贵宝公司在华合资企业),在京正式宣布双方已签署了战略合作协议。根据协议,双方将于2013年7月1日在华联合推广、销售格华止。公司在1999年成功上市格华止(二甲双胍),迄今已经使数百万2型糖尿病患者获益。格华止(二甲双胍)
On March 19, Merck Serono Co., a biopharmaceutical business unit of Merck Group, a former research enterprise of Merck AG, and Gehua Zhigao, the current production and sales enterprise in China, (Bristol-Myers Squibb joint venture in China) formally announced in Beijing that the two sides have signed a strategic cooperation agreement. According to the agreement, both parties will jointly promote and sell Gehua in China on July 1, 2013. The company was successfully listed in 1999 with metformin (metformin), which has so far benefited millions of people with type 2 diabetes. Gehua Zhizhi (metformin)